首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1547886

全球脂質紊亂治療市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

Global Lipid Disorder Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球脂質紊亂治療市場需求預計將從 2023 年的 85.7 億美元達到近 160.3 億美元的市場規模，2024-2032 年研究期間複合年成長率為 7.21%。

脂質紊亂是一種影響血脂水平的代謝疾病。這種情況會導致血液中低密度脂蛋白（LDL）膽固醇和三酸甘油酯的脂肪含量升高，或兩者兼而有之。高水平的低密度脂蛋白膽固醇和三酸甘油酯會增加心臟病的風險。這些水平可以透過一些主要選擇來降低，例如少吃脂肪、定期運動以及肥胖者減肥。然而，這些選擇並不總是有效。在這種情況下，醫生會開立藥物來控制膽固醇水平，對於許多患者來說，他汀類藥物等藥物可以有效降低膽固醇水平。其他藥物，包括膽汁酸螯合劑、纖維酸衍生物、膽固醇吸收抑制劑和菸鹼酸也可以幫助控制血脂水平。

市場動態

全球負擔的增加和老年人口的增加將推動市場的成長。血脂紊亂的盛行率日益增加已成為全球性的公共衛生問題。 2017年，全球估計有432萬人因低密度脂蛋白膽固醇過高而死亡。全球較易患脂質紊亂的老年人口的成長速度遠遠快於總人口的成長速度，預計至少到2050 年將繼續以更快的速度成長。外，某些生活方式，包括過量攝取飽和脂肪或反式脂肪含量高的食物、缺乏運動、肥胖和吸煙也會導致血脂紊亂。為了提高人們對血脂紊亂的預防、管理和治療的認知，政府正在促進健康飲食和身體活動的參與，早期發現和管理血脂紊亂，並定期更新和審查藥物清單和臨床方案，以確保公正地獲得經過驗證的安全性和有效性的藥物和療法。整體情況預計將使市場健康成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球脂質紊亂治療市場的每個細分市場進行了包容性評估。脂質紊亂治療產業的成長和趨勢為本研究提供了整體方法。

市場區隔

脂質紊亂治療市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

依藥物類型

阿托伐他汀
氟伐他汀
瑞舒伐他汀
辛伐他汀
普伐他汀
其他藥物

按配銷通路

零售藥局
醫院藥房
網路藥局

按指示

家族性混合性高血脂症
家族性缺陷載脂蛋白 B-100
家族性異常BETA脂蛋白血症
家族性高三酸甘油脂血症
雜合子家族性高膽固醇血症
其他適應症

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的脂質紊亂治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。脂質失調治療市場的主要參與者包括輝瑞公司、諾華公司、阿斯特捷利康公司、默克公司、Emcure Pharmaceuticals Ltd.、Teva Pharmaceuticals Industries Ltd.、Mylan NV、Kowa Pharmaceuticals America Inc.、Glenmark Pharmaceuticals Ltd.。、太陽製藥工業有限公司、沃克哈特有限公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：脂質紊亂治療公司的競爭格局

脂質紊亂治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
Pfizer Inc.

公司概況
公司收入
產品
最新動態

Novartis AG

公司概況
公司收入
產品
最新動態

AstraZeneca

公司概況
公司收入
產品
最新動態

Merck & Co. Inc.

公司概況
公司收入
產品
最新動態

Emcure Pharmaceuticals Ltd.

公司概況
公司收入
產品
最新動態

Teva Pharmaceuticals Industries Ltd.

公司概況
公司收入
產品
最新動態

Mylan NV

公司概況
公司收入
產品
最新動態

Kowa Pharmaceuticals America Inc.

公司概況
公司收入
產品
最新動態

Glenmark Pharmaceuticals Ltd.

公司概況
公司收入
產品
最新動態

Sun Pharmaceuticals Industries Ltd.

公司概況
公司收入
產品
最新動態

Wockhardt Limited

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11212596

The global demand for Lipid Disorder Treatment Market is presumed to reach the market size of nearly USD 16.03 Billion by 2032 from USD 8.57 Billion in 2023 with a CAGR of 7.21% under the study period 2024-2032.

Lipid disorder is a metabolic condition that affects blood lipid levels. The condition causes high blood levels of low-density lipoprotein (LDL) cholesterol, and fats called triglycerides or both. High levels of LDL cholesterol and triglycerides increase the risk of developing heart disease. These levels can be reduced by some primary options such as eating less fat, exercising regularly and losing weight if one is obese. However, these options are not always effective. In such cases medication is prescribed to control the level, medications, such as statins, are effective in lowering cholesterol levels for many patients. Other medications, including bile acid sequestrants, fibric acid derivatives, cholesterol absorption inhibitors, and niacin can also help control lipid levels.

MARKET DYNAMICS

The rising global burden and growing geriatric population will be driving the growth of the market. The increasing prevalence of lipid disorders has become a global public health problem. In 2017, 4.32 million deaths were estimated owing to high low-density lipoprotein cholesterol globally. Globally geriatric population who are more prevelant to lipipd disorder is growing considerably faster than the population as a whole, and it is expected to continue growing more rapidly at least till 2050. Apart from ageing, gender, genetic susceptibility, chronic diseases, medications, certain lifestyles including excessive intake of foods high in saturated or trans fats, physical inactivity, obesity and smoking also contribute to blood lipid disorders. To bring awareness about prevention, management, and treatment of blood lipid disorders, the Government is promoting a healthy diet and physical activity participation, early detection and management of blood lipid disorders as well as update and review of drug lists and clinical protocols regularly to ensure impartial access to drugs and therapies of proven safety and efficacy. The overall scenario is predicted to make healthy growth of the market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Lipid Disorder Treatment. The growth and trends of Lipid Disorder Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Lipid Disorder Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

Atorvastatin
Fluvastatin
Rosuvastatin
Simvastatin
Pravastatin
Other Drugs

By Distribution Channel

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

By Indication

Familial Combined Hyperlipidemia
Familial Defective Apolipoprotein B-100
Familial Dysbetalipoproteinemia
Familial Hypertriglyceridemia
Heterozygous Familial Hypercholesterolemia
Other Indications

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Lipid Disorder Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Lipid Disorder Treatment market include Pfizer Inc., Novartis AG, AstraZeneca, Merck & Co. Inc., Emcure Pharmaceuticals Ltd., Teva Pharmaceuticals Industries Ltd., Mylan N.V., Kowa Pharmaceuticals America Inc., Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., Wockhardt Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. LIPID DISORDER TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Distribution Channel
- 3.7.3 Market Attractiveness Analysis By Indication
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL LIPID DISORDER TREATMENT MARKET ANALYSIS BY DRUG TYPE

5.1. Overview By Drug Type
5.2. Historical and Forecast Data
5.3. Analysis By Drug Type
5.4. Atorvastatin Historic and Forecast Sales By Regions
5.5. Fluvastatin Historic and Forecast Sales By Regions
5.6. Rosuvastatin Historic and Forecast Sales By Regions
5.7. Simvastatin Historic and Forecast Sales By Regions
5.8. Pravastatin Historic and Forecast Sales By Regions
5.9. Other Drugs Historic and Forecast Sales By Regions

6. GLOBAL LIPID DISORDER TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

6.1. Overview By Distribution Channel
6.2. Historical and Forecast Data
6.3. Analysis By Distribution Channel
6.4. Retail Pharmacies Historic and Forecast Sales By Regions
6.5. Hospital Pharmacies Historic and Forecast Sales By Regions
6.6. Online Pharmacies Historic and Forecast Sales By Regions

7. GLOBAL LIPID DISORDER TREATMENT MARKET ANALYSIS BY INDICATION

7.1. Overview By Indication
7.2. Historical and Forecast Data
7.3. Analysis By Indication
7.4. Familial Combined Hyperlipidemia Historic and Forecast Sales By Regions
7.5. Familial Defective Apolipoprotein B-100 Historic and Forecast Sales By Regions
7.6. Familial Dysbetalipoproteinemia Historic and Forecast Sales By Regions
7.7. Familial Hypertriglyceridemia Historic and Forecast Sales By Regions
7.8. Heterozygous Familial Hypercholesterolemia Historic and Forecast Sales By Regions
7.9. Other Indications Historic and Forecast Sales By Regions

8. GLOBAL LIPID DISORDER TREATMENT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE LIPID DISORDER TREATMENT COMPANIES

9.1. Lipid Disorder Treatment Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF LIPID DISORDER TREATMENT INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Pfizer Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Novartis AG
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. AstraZeneca
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Merck & Co. Inc.
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Emcure Pharmaceuticals Ltd.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Teva Pharmaceuticals Industries Ltd.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Mylan N.V.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Kowa Pharmaceuticals America Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Glenmark Pharmaceuticals Ltd.
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Sun Pharmaceuticals Industries Ltd.
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Wockhardt Limited
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments